Equities

SinoMab BioScience Ltd

SinoMab BioScience Ltd

Actions
  • Price (HKD)1.23
  • Today's Change0.01 / 0.82%
  • Shares traded1.06m
  • 1 Year change+4.24%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments235376563
Total Receivables, Net------
Total Inventory------
Prepaid expenses3.22126.16
Other current assets, total325927
Total current assets270447596
Property, plant & equipment, net575486356
Goodwill, net------
Intangibles, net1.842.601.92
Long term investments--027
Note receivable - long term------
Other long term assets1.107361
Total assets8481,0081,042
LIABILITIES
Accounts payable------
Accrued expenses5.44117.46
Notes payable/short-term debt000
Current portion long-term debt/capital leases714612
Other current liabilities, total9613179
Total current liabilities17318798
Total long term debt380311263
Total debt451357275
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities552499361
SHAREHOLDERS EQUITY
Common stock1,7251,7251,679
Additional paid-in capital------
Retained earnings (accumulated deficit)(1367)(1140)(857)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(9.73)(20)(82)
Total equity296510680
Total liabilities & shareholders' equity8481,0081,042
Total common shares outstanding1,0351,0351,006
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.